$0.284
-0.004 (-1.46%)Zum Schluss
Umsatzquellen von MRM
Medirom Healthcare Technologies Inc (MRM) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Relaxation Salon, accounting for 99.2% of total sales, equivalent to JPY 2.11B. Other significant revenue streams include Revenue from directly-operated salons and Sublease revenue. Understanding this composition is critical for investors evaluating how MRM navigates market cycles within the Personal Services industry.
Profitabilität und Margen von MRM
Evaluating the bottom line, Medirom Healthcare Technologies Inc maintains a gross margin of 99.65%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 11.54%, while the net margin is 10.36%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively MRM converts its operational activities into shareholder value.
MRM im Vergleich zur Peergroup
In the context of the broader market, MRM competes directly with industry leaders such as EJH and AMBO. With a market capitalization of $2.25M, it holds a significant position in the sector. When comparing efficiency, MRM's gross margin of 99.65% stands against EJH's 23.42% and AMBO's 51.40%. Such benchmarking helps identify whether Medirom Healthcare Technologies Inc is trading at a premium or discount relative to its financial performance.
Finanzielle Entwicklung von Medirom Healthcare Technologies Inc
Medirom's gross margin has shown remarkable improvement, reaching 99.65% in the last quarter, while net income has turned positive at 63,427,822 JPY for the last two quarters. However, the company has a negative P/E ratio of -0.002044 and a price-to-sales ratio of 0.000283, indicating severe undervaluation and financial distress.
Financials
Ähnliche Artikel
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.